undamentalytics Newsletter

Perspective Therapeutics, Inc. valuation and forecast

Explore the models for Perspective Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

16 analysts, Oct 2026
Buy1488%
Hold213%
Sell00%

Monthly trend

  1. Oct 202613216
  2. Sep 202621316
  3. Aug 202621215
  4. Jul 202621215

Counts of recommendations published by analysts covering Perspective Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

CATX valuation questions

How does Fundamentalytics value Perspective Therapeutics, Inc.?
We use the models that fit Perspective Therapeutics, Inc.'s business and available financial data: growth cash-flow model. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Perspective Therapeutics, Inc.

Compare with peers